Rino S. Seedor, MD, assistant professor, Sidney Kimmel Cancer Center, Jefferson Health, discusses findings from the phase 3 DREAMseq trial (NCT02224781), which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.
Video Reports
Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic Melanoma
Zeynep Eroglu, MD, medical oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center, assistant professor, Department of Oncologic Sciences, the University of South Florida, Morsani College of Medicine, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.
Overview of Metastatic Uveal Melanoma
Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.